Cancer therapy
AssigneeTriact Therapeutics, Inc.
InventorsThomas F. WHITE, Edward F. SCHNIPPER, Dan HOTH
Life of this patent
Estimating the term…
Loading patent…
AssigneeTriact Therapeutics, Inc.
InventorsThomas F. WHITE, Edward F. SCHNIPPER, Dan HOTH
Estimating the term…
The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor. Catecholic butanes cane serve as dual kinase inhibitors for purposes of methods described herein. Subjects can be further treated by co-administering an EGFR inhibitor. The present application also relates to analyzing a sample with respect to levels of IGF-1R and EGFR and comparing levels of IGF-1R and EGFR to a control. Patients can be selected for treatment with a catecholic butane based on the assessment; optionally, patients can be further treated with an EGFR inhibitor, an IGF-1R inhibitor, or both.
A method for treating a disease in a subject, wherein the subject has developed resistance to treatment with one or more tyrosine-kinase inhibitors, comprising administering an effective amount of a pharmaceutical compound capable of inhibiting the tyrosine kinase activity of both IGF-1R and EGFR.
A method for treating cancer in a subject, wherein said subject has developed resistance to treatment with one or more tyrosine-kinase inhibitors, comprising administering an effective amount of a pharmaceutical composition capable of inhibiting the tyrosine kinase activity of both IGF-1R and EGFR, wherein the pharmaceutical composition comprises a catecholic butane.
A method for determining a disease treatment, comprising:
A method of selecting a subject for treatment with a dual tyrosine kinase inhibitor capable of inhibiting the tyrosine kinase activity of both IGF-1R and EGF-R, wherein said subject is identified as having levels of IGF-1R, EGFR, or both at baseline levels or at 2× greater than baseline levels as compared to control levels.
Dependencies are inferred from the claim text.